Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized clinically by memory and cognitive dysfunction. Unfortunately, there is no effective therapeutic method for AD treatment or ways to halt disease progression. Many mechanisms are involved in the disease, including genes mutation and protein dysfunction. RNA interference (RNAi) technology may potentially be able to control AD. It can inhibit the protein expression of specific genes by activating a sequence-specific RNA degradation process. This is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we highlight the advances in RNAi technology in the investigation and treatment of AD. © 2013 Chen et al, publisher and licensee Dove Medical Press Ltd.
CITATION STYLE
Chen, S., Ge, X., Chen, Y., Lv, N., Liu, Z., & Yuan, W. (2013, February 21). Advances with RNA interference in Alzheimer’s disease research. Drug Design, Development and Therapy. https://doi.org/10.2147/DDDT.S40229
Mendeley helps you to discover research relevant for your work.